Ceruloplasmin deficiency promotes osteoclast cuproptosis-like cell death and is associated with higher bone mass in OVX mice with coordinated activation of AMPK/p53 signaling
Abstract
Osteoclast bone resorption consumes a large amount of energy, and its energy metabolism disorder is an important pathogenesis of bone metabolism diseases such as osteoporosis. Excessive copper ions interfere with the energy metabolism of the mitochondrial tricarboxylic acid cycle, leading to cuproptosis—a recently identified form of regulated cell death. Ceruloplasmin (CP), a major copper-binding protein, is associated with osteoporosis. However, the role and mechanism of CP in regulating osteoclast energy metabolism in association with osteoclast cuproptosis remain unclear. Our research found that CP inhibited elesclomol-copper (ES-Cu)-induced osteoclast cuproptosis-like cell death, thereby promoting osteoclast formation and overall bone resorption. CP downregulated the expression of cuproptosis-related genes ( Lipt1 , Gls , Pdhb , Fdx1 , Dlat , and Pdha1 ) in osteoclasts. In vivo, CP deficiency preserved higher bone mass in OVX mice at the macroscopic tissue level. Mechanistically, CP suppressed ES-Cu-induced AMPK/p53 pathway activation during osteoclastogenesis. Notably, the direct causal relationship between AMPK/p53 signaling and CP-modulated osteoclast cuproptosis has not been definitively established in this study, and the observed regulatory correlation requires further rigorous functional verification. Targeting CP may represent a potential therapeutic strategy for postmenopausal osteoporosis by inducing osteoclast cuproptosis.
Related
- Copper Ceruloplasmin as a Potential Biomarker of Biliary Tract Cancers: A Pilot Study
- BRCA1 Mutation-Recognizing Tetrahedral Framework Nucleic Acid Nanoplatform Enables Coordinated PARP/WEE1 Inhibition and STING-Associated Antitumor Immunity in Ovarian Cancer.
- Integrated Transcriptomic and Biochemical Analyses Reveal Coordinated Suppression of ER-Associated Survival Signaling and Activation of ROS-Mediated Stress Responses by Oxidized Graphene Quantum Dots in Estrogen Receptor-Positive Breast Cancer
- Coordinated P450–UGT detoxification contributes to furanocoumarin tolerance associated with host plant range divergence in Helicoverpa
- Distinct osteoclast transcriptional states and heterotypic fusion arising from circulating pre-dendritic cells and monocytes
BibTeX
@article{chen2026ceruloplasmin,
title = {{Ceruloplasmin deficiency promotes osteoclast cuproptosis-like cell death and is associated with higher bone mass in OVX mice with coordinated activation of AMPK/p53 signaling}},
author = {Guiping Chen and Feng Yan and Qiangqiang Xiong and Qiangping Zhou and Shishi Jiang},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-75196-7},
url = {https://www.nature.com/articles/s41598-026-75196-7},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Ceruloplasmin deficiency promotes osteoclast cuproptosis-like cell death and is associated with higher bone mass in OVX mice with coordinated activation of AMPK/p53 signaling
AU - Guiping Chen
AU - Feng Yan
AU - Qiangqiang Xiong
AU - Qiangping Zhou
AU - Shishi Jiang
PY - 2026
DA - 2026/10/08
JO - Scientific Reports
DO - 10.1038/s41598-026-75196-7
UR - https://www.nature.com/articles/s41598-026-75196-7
AB - Osteoclast bone resorption consumes a large amount of energy, and its energy metabolism disorder is an important pathogenesis of bone metabolism diseases such as osteoporosis. Excessive copper ions interfere with the energy metabolism of the mitochondrial tricarboxylic acid cycle, leading to cuproptosis—a recently identified form of regulated cell death. Ceruloplasmin (CP), a major copper-binding protein, is associated with osteoporosis. However, the role and mechanism of CP in regulating osteoclast energy metabolism in association with osteoclast cuproptosis remain unclear. Our research found that CP inhibited elesclomol-copper (ES-Cu)-induced osteoclast cuproptosis-like cell death, thereby promoting osteoclast formation and overall bone resorption. CP downregulated the expression of cuproptosis-related genes ( Lipt1 , Gls , Pdhb , Fdx1 , Dlat , and Pdha1 ) in osteoclasts. In vivo, CP deficiency preserved higher bone mass in OVX mice at the macroscopic tissue level. Mechanistically, CP suppressed ES-Cu-induced AMPK/p53 pathway activation during osteoclastogenesis. Notably, the direct causal relationship between AMPK/p53 signaling and CP-modulated osteoclast cuproptosis has not been definitively established in this study, and the observed regulatory correlation requires further rigorous functional verification. Targeting CP may represent a potential therapeutic strategy for postmenopausal osteoporosis by inducing osteoclast cuproptosis.
SN - 2045-2322
ER -